Rituximab for treatment of Opsoclonus-myoclonus syndrome in neuroblastoma

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 679-680

  Burke, Michael J ^a   Cohn, Susan L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Neuroblastoma; Opsoclonus myoclonus; Rituximab

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ABSENCE OF SIDE EFFECTS; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CONTINUOUS INFUSION; DISEASE ASSOCIATION; HUMAN; LOW DRUG DOSE; MALE; NEUROBLASTOMA; NEUROLOGIC DISEASE; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RARE DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADRENAL GLAND NEOPLASMS; ANTIBODIES, MONOCLONAL; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DIAGNOSTIC ERRORS; GANGLIONEUROBLASTOMA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEARNING DISORDERS; MALE; OPSOCLONUS-MYOCLONUS SYNDROME; PSYCHOMOTOR DISORDERS; RECURRENCE;

EID: 38549143161     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21009     Document Type: Article

References (15)

1. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcomes and anti-neuronal antibodies - A report from the Children's Cancer Group Study. Med Pediatr Oncol 2001;36:612-622.
2. Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992;15:186-228.
3. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 1976;37:846-852.
4. Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994;125:712-716.
5. Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. Med Ped Oncol 1997;28:284-288.
6. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: Developmental and neurologic sequelae. Pediatrics 2002;109:86-98.
7. Howard K, Jeremy RJ, Jenkins S. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: Relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001;139:552-559.
8. Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995;127:328-329.
9. Borgna-Pignatti C, Baiter R, Marradi P, et al. Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus. J Pediatr 1996;129:179-180.
10. Veneselli E, Conte M, Biancheri R. et al. Effect of steroid and high dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol 1998;30:15-17.
11. Yiu VW, Kovithavongs T, McGonigle LF, et al. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001;24:72-74.
12. Sheela SR, Mani PJ. Opsoclonus-myoclonus syndrome: response to plasmapheresis. Indian Pediatr 2004;41:499-502.
13. Pranzatelli MR, Tate ED, Travelstead AL, et al. Immunologic and clinical responses to Rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005;115:115-119.
14. Bell J, Moran C, Blatt J. Response to Rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2006; [E-pub ahead of print].
15. Maloney DG, Liles TM, Czerwinski C, et al. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.